Printer Friendly

Neuronetics to sell and distribute NeuroStar Advanced Therapy system for Major Depressive Disorder (MDD) in Japan upon Shonin approval.

M2 PHARMA-October 12, 2017-Neuronetics to sell and distribute NeuroStar Advanced Therapy system for Major Depressive Disorder (MDD) in Japan upon Shonin approval

(C)2017 M2 COMMUNICATIONS

Medical device company Neuronetics Inc reported on Wednesday the receipt of the Shonin approval from Japan's Ministry of Health, Labor and Welfare to sell and distribute its NeuroStar Advanced Therapy system for the treatment of Major Depressive Disorder (MDD) in the country.

The company said its NeuroStar Advanced Therapy is the first transcranial magnetic stimulation to be selected as a safe and effective non-drug treatment option for Major Depressive Disorder (MDD) in Japan.

NeuroStar Advanced Therapy is a non-invasive treatment that uses MRI strength magnetic pulses to stimulate areas of the brain that are underactive in depression. NeuroStar Advanced Therapy is the established leader in transcranial magnetic stimulation (TMS), a non-invasive form of neuromodulation.

About 3m people in Japan are reportedly diagnosed with depression and the country faces one of the highest suicide rates in the world.

Under the company's open-label clinical trial, 58% of patients significantly responded to treatment and 37% achieved complete remission of their depression symptoms. Additionally, NeuroStar Advanced Therapy's sophisticated technology provides physicians with real-time feedback and delivers reliable and consistent treatment, allowing for the right treatment dose to be delivered to the right location every time, giving patients the best possible chance for long-term remission.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:9JAPA
Date:Oct 12, 2017
Words:237
Previous Article:Samsung BioLogics awarded first US FDA approval at the world's largest biologics drug substance plant.
Next Article:Longevity Biotech wins US patent for hybridtide platform technology for stabilized peptide therapeutics.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters